Farnesyl transferase inhibitor resistance probed by target mutagenesis

Blood

Volumn 110, Issue 6, 2007, Pages 2102-2109

  Raz, Tal ^a,b   Nardi, Valentina ^a,b   Azam, Mohammad ^a,b   Cortes, Jorge ^c   Daley, George Q ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; LONAFARNIB; ONCOPROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL CULTURE; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; MUTAGENESIS; MYELOID LEUKEMIA; NONHUMAN; PRENYLATION; PRIORITY JOURNAL;

EID: 34548845301     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-064907     Document Type: Article

References (45)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653.
2. Hampton T. Looking beyond imatinib next line of targeted drugs for CML shows promise. JAMA. 2006;295:369-370.
3. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993;260:1934-1937.
4. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. J Biol Chem. 2003;278:32493-32496.
5. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
6. James G, Goldstein JL, Brown MS. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci U S A. 1996;93:4454-4458.
7. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459-14464.
8. Basso AD, Kirschmeier P, Bishop WR. Thematic review series: lipid posttranslational modifications: farnesyl transferase inhibitors. J Lipid Res. 2006;47:15-31.
9. Lancet JE, Gojo I, Gotlib J, et al. A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2006;109:1387-1394.
10. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
11. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
12. Eskens FA, Awada A, Cutler DL, et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001;19:1167-1175.
13. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood. 2005;106:4322-4329.
14. Jorgensen HG, Allan EK, Graham SM, et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia. 2005;19:1184-1191.
15. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res. 2001;7:1438-1445.
16. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
17. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004;45:2187-2195.
18. Buckner FS, Eastman RT, Yokoyama K, Gelb MH, Van Voorhis WC. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs. 2005;6:791-797.
19. Fong LG, Frost D, Meta M, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science. 2006;311:1621-1623.
20. Yang SH, Meta M, Qiao X, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest. 2006;116:2115-2121.
21. Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res. 2002;8:2002-2009.
22. Buzzeo R, Enkemann S, Nimmanapalli R, et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res. 2005;11:6057-6064.
23. Zhang B, Groffen J, Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood. 2005;106:1355-1361.
24. Bruzek LM, Poynter JN, Kaufmann SH, Adjei AA. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)- cyclohepta(1,2- b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1- piperidinecarboxamide (SCH66336). Mol Pharmacol. 2005;68:477-486.
25. Del Villar K, Urano J, Guo L, Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem. 1999;274:27010-27017.
26. Eastman RT, White J, Hucke O, et al. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem. 2005;280:13554-13559.
27. Eastman RT, White J, Hucke O, et al. Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol. 2007;152:66-71.
28. Heidel F, Solem FK, Breitenbuecher F, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006;107:293-300.
29. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-792.
30. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73:225-235.
31. Koh EY, Chen T, Daley GQ. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 2002;30:e142:1-7.
32. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18:3587-3596.
33. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
34. Azam M, Raz T, Nardi V, Opitz SL, Daley GQ. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003;5:204-210.
35. Naviaux RK, Costanzi E, Haas M, Verma IM. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol. 1996;70:5701-5705.
36. Rasband WS. ImageJ, U.S. Bethesda, MD: National Institutes of Health; 1997-2006.
37. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International. 2004;11:36-42.
38. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112:831-843.
39. Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006;24:507-516.
40. Winquist E, Moore MJ, Chi KN, et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol. 2005;23:143-149.
41. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6:2318-2325.
42. Strickland CL, Weber PC, Windsor WT, et al. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem. 1999;42:2125-2135.
43. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science. 1997;275:1800-1804.
44. Pickett JS, Bowers KE, Fierke CA. Mutagenesis studies of protein farnesyltransferase implicate aspartate beta 352 as a magnesium ligand. J Biol Chem. 2003;278:51243-51250.
45. Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem. 1997;272:680-687.